Development of a human antibody tolerant mouse model to assess the immunogenicity risk due to aggregated biotherapeutics

Journal of Pharmaceutical Sciences

Volumn 102, Issue 10, 2013, Pages 3545-3555

  Bi, Vivian ^a   Jawa, Vibha ^a   Joubert, Marisa K ^a   Kaliyaperumal, Arunan ^a   Eakin, Catherine ^b   Richmond, Karen ^a   Pan, Oscar ^a   Sun, Jilin ^a   Hokom, Martha ^a   Goletz, Theresa J ^b   Wypych, Jette ^a   Zhou, Lei ^a   Kerwin, Bruce A ^b   Narhi, Linda O ^a   Arora, Taruna ^c  

^a AMGEN INC   (United States)

^b AMGEN INC   (United States)

^c Antibody Engineering   (United States)

Author keywords

ADA; Immunogenicity risk; Immunology; Mouse models; Oxidation; Particle size; Physiological model; Protein aggregation; Stability; Tolerance

Indexed keywords

ANTIBODY; B LYMPHOCYTE ANTIGEN; IMMUNOGLOBULIN G2; MONOCLONAL ANTIBODY; MONOMER;

ANIMAL EXPERIMENT; ARTICLE; CELL AGGREGATION; CHEMICAL MODIFICATION; CONTROLLED STUDY; CROSS BREEDING; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LONG TERM MEMORY; MEMORY CELL; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; OXIDATION; RISK FACTOR; WILD TYPE;

ADA; IMMUNOGENICITY RISK; IMMUNOLOGY; MOUSE MODELS; OXIDATION; PARTICLE SIZE; PHYSIOLOGICAL MODEL; PROTEIN AGGREGATION; STABILITY; TOLERANCE;

ANIMALS; ANTIBODIES; ANTIBODY FORMATION; B-LYMPHOCYTES; BIOLOGICAL FACTORS; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES;

EID: 84883811790     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23663     Document Type: Article

References (46)

1. Koren E, Smith HW, Shores E, Shankar G, Finco-Kent D, Rup B, Barrett YC, Devanarayan V, Gorovits B, Gupta S, Parish T, Quarmby V, Moxness M, Swanson SJ, Taniguchi G, Zuckerman LA, Stebbins CC, Mire-Sluis A 2008. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods 333:1-9.
2. Ponce R, Abad L, Amaravadi L, Gelzleichter T, Gore E, Green J, Gupta S, Herzyk D, Hurst C, Ivens IA, Kawabata T, Maier C, Mounho B, Rup B, Shankar G, Smith H, Thomas P, Wierda D. 2009 Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol 54:164-182.
3. CBER, Draft Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products (February 2013) can be accessed at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338856.pdf.
4. EMEA, Guideline on Strategies to Identify and Mitigate Risks for First-inhuman Clinical Trials with Investigational Medicinal Products (July 2007) can be accessed at: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002988.pdf.
5. Bryson CJ, Jones TD, Baker MP. 2010. Prediction of immunogenicity of therapeutic proteins: Validity of computational tools. BioDrugs 24:1-8.
6. Lundegaard C, Lund O, Nielsen M. 2012. Predictions versus high-throughput experiments in T-cell epitope discovery: Competition or synergy? Expert Rev Vaccines 11:43-54.
7. Bee JS, Goletz TJ, Ragheb JA. 2012. The future of protein particle characterization and understanding its potential to diminish the immunogenicity of biopharmaceuticals: A shared perspective. J Pharm Sci 101:3580-3585.
8. Singh SK. 2011. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 100:354-387.
9. Zhang W, Liu J, Niu Y. 2010. Quantitative prediction of MHC-II binding affinity using particle swarm optimization. Artif Intell Med 50:127-132.
10. Stickler M, Chin R, Faravashi N, Gebel W, Razo OJ, Rochanayon N, Power S, Valdes AM, Holmes S, Harding FA. 2003. Human population-based identification of CD4(+) T-cell peptide epitope determinants. J Immunol Methods 281:95-108.
11. Wullner D, Zhou L, Bramhall E, Kuck A, Goletz TJ, Swanson S, Chirmule N, Jawa V. 2010. Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics. Clin Immunol 137:5-14.
12. Soccio RE, Tuteja G, Everett LJ, Li Z, Lazar MA, Kaestner KH. 2011. Species-specific strategies underlying conserved functions of metabolic transcription factors. Mol Endocrinol 25:694-706.
13. Nielsen M, Lundegaard C, Lund O. 2007. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics 8:238.
14. Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin U, Braxenthaler M, Gallazzi F, Protti MP, Sinigaglia F, Hammer J. 1999. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 17:555-561.
15. Tenzer S, Peters B, Bulik S, Schoor O, Lemmel C, Schatz MM, Kloetzel PM, Rammensee HG, Schild H, Holzhutter HG. 2005. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell Mol Life Sci 62:1025-1037.
16. Peters B, Bulik S, Tampe R, Van Endert PM, Holzhutter HG. 2003. Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors. J Immunol 171:1741-1749.
17. Harding FA, Stickler MM, Razo J, DuBridge RB. 2010. The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions. MAbs 2:256-265.
18. Jaber JR, Perez J, Arbelo M, Herraez P, Espinosa de los Monteros A, Rodnguez F, Fernandez T, Fernandez A. 2003. Immunophenotypic characterization of hepatic inflammatory cell infiltrates in common dolphins (Delphinus delphis). J Comp Pathol 129:226-230.
19. Jaber A, Baker M. 2007. Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays. J Pharm Biomed Anal 43:1256-1261.
20. Joubert MK, Hokom M, Eakin C, Zhou L, Deshpande M, Baker MP, Goletz TJ, Kerwin BA, Chirmule N, Narhi LO, Jawa V. 2012. Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem 287:25266-25279.
21. Hermeling S, Jiskoot W, Crommelin D, Bornaes C, Schellekens H. 2005. Development of a transgenic mouse model immune tolerant for human interferon Beta. Pharm Res 22:847-851.
22. Hermeling S, Schellekens H, Maas C, Gebbink MF, Crommelin DJ, Jiskoot W. 2006. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci 95:1084-1096.
23. van Beers MM, Sauerborn M, Gilli F, Brinks V, Schellekens H, Jiskoot W. 2010. Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice. Pharm Res 27:1812-1824.
24. van Beers MM, Sauerborn M, Gilli F, Brinks V, Schellekens H, Jiskoot W. 2011. Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice. Pharm Res 28:2393-2402.
25. Ramani K, Purohit V, Miclea R, Gaitonde P, Straubinger RM, Balu-Iyer SV 2008. Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A. J Pharm Sci 97:3753-3764.
26. Braun A, Kwee L, Labow MA, Alsenz J. 1997. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res 14:1472-1478.
27. Purohit VS, Middaugh CR, Balasubramanian SV. 2006. Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice. J Pharm Sci 95:358-371.
28. Green LL. 1999. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods 231:11-23.
29. Gallo ML, Ivanov VE, Jakobovits A, Davis CG. 2000. The human immunoglobulin loci introduced into mice: V (D) and J gene segment usage similar to that of adult humans. Eur J Immunol 30:534-540.
30. Mendez MJ, Green LL, Corvalan JR, Jia XC, Maynard-Currie CE, Yang XD, Gallo ML, Louie DM, Lee DV, Erickson KL, Luna J, Roy CM, Abderrahim H, Kirschenbaum F, Noguchi M, Smith DH, Fukushima A, Hales JF, Klapholz S, Finer MH, Davis CG, Zsebo KM, Jakobovits A. 1997. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet 15:146-156.
31. Taneja V, David CS. 1999. HLA class II transgenic mice as models of human diseases. Immunol Rev 169:67-79.
32. Brehm MA, Cuthbert A, Yang C, Miller DM, DiIorio P, Laning J, Burzenski L, Gott B, Foreman O, Kavirayani A, Herlihy M, Rossini AA, Shultz LD, Greiner DL. 2010. Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation. Clin Immunol 135:84-98.
33. Ishikawa F, Saito Y, Yoshida S, Harada M, Shultz LD. 2008. The differentiative and regenerative properties of human hematopoietic stem/progenitor cells in NOD-SCID/IL2rgamma(null) mice. Curr Top Microbiol Immunol 324:87-94.
34. Reddy P, Negrin R, Hill GR. 2008. Mouse models of bone marrow transplantation. Biol Blood Marrow Transplant 14:129-135.
35. Wege AK, Melkus MW, Denton PW, Estes JD, Garcia JV. 2008. Functional and phenotypic characterization of the humanized BLT mouse model. Curr Top Microbiol Immunol 324:149-165.
36. Green LL, Jakobovits A. 1998. Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes. J Exp Med 188:483-495.
37. Joubert MK, Luo Q, Nashed-Samuel Y, Wypych J, Narhi LO. 2011. Classification and characterization of therapeutic antibody aggregates. J Biol Chem 286:25118-25133.
38. Luo Q, Joubert MK, Stevenson R, Ketchem RR, Narhi LO, Wypych J. 2011. Chemical modifications in therapeutic protein aggregates generated under different stress conditions. J Biol Chem 286:25134-25144.
39. Alexander J, del Guercio MF, Maewal A, Qiao L, Fikes J, Chesnut RW, Paulson J, Bundle DR, DeFrees S, Sette A. 2000. Linear PADRET helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J Immunol 164:1625-1633.
40. Moxness M, Tatarewicz S, Weeraratne D, Murakami N, Wullner D, Mytych D, Jawa V, Koren E, Swanson SJ. 2005. Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies. Clin Chem 51:1983-1985.
41. Bautista AC, Wullner D, Moxness M, Swanson SJ, Chirmule N, Jawa V. 2010. Impact of matrix-associated soluble factors on the specificity of the immunogenicity assessment. Bioanalysis 2:721-731.
42. Filipe V, Jiskoot W, Basmeleh AH, Halim A, Schellekens H. 2012. Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice. MAbs 4:740-752.
43. Fradkin AH, Carpenter JF, Randolph TW. 2009. Immunogenicity of aggregates of recombinant human growth hormone in mouse models. J Pharm Sci 98:3247-3264.
44. Prokopec KE, Rhodiner M, Matt P, Lindqvist U, Kleinau S. 2010. Down regulation of Fc and complement receptors on B cells in rheumatoid arthritis. Clin Immunol 137:322-329.
45. Hochuli E. 1997. Interferon immunogenicity: Technical evaluation of interferon-alpha 2a. J Interferon Cytokine Res 17 Suppl 1:S15-S21.
46. Agarwal MM, Mandal AK, Agarwal S, Lal A, Prakash M, Mavuduru R, Singh SK. 2010. Surgicel granuloma: Unusual cause of "recurrent" mass lesion after laparoscopic nephron-sparing surgery for renal cell carcinoma. Urology 76:334-335.